Celldex Therapeutics, Inc
CLDXCelldex Therapeutics, Inc. is a biotechnology company focused on developing targeted immunotherapies for cancer and other diseases. The company specializes in monoclonal antibodies, recombinant proteins, and vaccine technologies to stimulate the immune system's ability to fight tumors. Founded in 2004 and based in Hampton, New Jersey, Celldex aims to advance innovative treatments through a pipeline of clinical and preclinical candidates.
Company News
The global CIndU market is experiencing significant growth driven by advancements in diagnostic tools, biologic therapies, and increasing awareness of immune mechanisms, with emerging personalized medicine approaches promising improved patient outcomes.
Celldex's barzolvolimab demonstrated rapid, robust, and durable improvements in angioedema symptoms over 52 weeks in a Phase 2 study for chronic spontaneous urticaria, with up to 77% of patients being angioedema-free at Week 52.
Celldex Therapeutics presented positive preclinical data for its bispecific antibody CDX-622, which targets TSLP and SCF to reduce inflammation and fibrosis. The data showed CDX-622 inhibits TSLP and SCF-dependent activities, and a Phase 1 study in healthy volunteers is ongoing.
Celldex Therapeutics announced positive data from Phase 2 studies of its drug barzolvolimab in patients with chronic urticaria, demonstrating improved disease control and quality of life.
The chronic spontaneous urticaria market is expected to grow due to increased disease prevalence, improved diagnosis, and the launch of new therapies. Key companies working on innovative treatments include Novartis, Sanofi, Regeneron, Celldex Therapeutics, Jasper Therapeutics, and others.
